Regeneron Pharmaceuticals Inc (NASDAQ:REGN) saw some unusual options trading on Tuesday. Stock investors acquired 389 put options on the company. This represents an increase of approximately 232% compared to the typical volume of 117 put options.

A number of brokerages have weighed in on REGN. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective for the company. in a research note on Monday, May 15th. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a report on Monday, May 15th. Cowen and Company reissued a “hold” rating and issued a $380.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Credit Suisse Group AG reissued a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Finally, Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $432.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.270% during midday trading on Tuesday, reaching $459.745. 316,944 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $464.40. The stock has a market cap of $48.54 billion, a P/E ratio of 55.652 and a beta of 1.44. The company’s 50-day moving average price is $401.76 and its 200-day moving average price is $383.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same period last year, the company posted $2.57 EPS. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post $12.67 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the director now owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $400,000. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of REGN. Korea Investment CORP boosted its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Live Your Vision LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $157,000. Finally, Blenheim Capital Management BV bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $160,000. 68.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Stock Traders Purchase High Volume of Put Options on Regeneron Pharmaceuticals (REGN)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/05/23/stock-traders-purchase-high-volume-of-put-options-on-regeneron-pharmaceuticals-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

12 Month Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.